A. Yver

发表

A simplified interventional mapping system (SIMS) for the selection of combinations of targeted treatments in non-small cell lung cancer

Pierre Validire, Yudi Pawitan, Angel Porgador, 2015, Oncotarget.

Mobilization of CD34+ cells by glycosylated and nonglycosylated G‐CSF in healthy volunteers — a comparative study

T. Tötterman, M. Höglund, A. Yver, 1997, European journal of haematology.

Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive breast cancer previously treated with trastuzumab emtansine: a dose-expansion, phase 1 study.

C. Redfern, H. Iwata, K. Tamura, 2019, The Lancet. Oncology.

Trastuzumab deruxtecan (DS-8201a) in subjects with HER2-expressing solid tumors: Long-term results of a large phase 1 study with multiple expansion cohorts.

C. Redfern, H. Iwata, K. Tamura, 2018 .

Ulceration and stage are predictive of interferon efficacy in melanoma: results of the phase III adjuvant trials EORTC 18952 and EORTC 18991.

D. Schadendorf, R. Dummer, A. Testori, 2012, European journal of cancer.

Development and validation of a real-time PCR assay for the detection and quantitation of p53 recombinant adenovirus in clinical samples from patients treated with Ad5CMV-p53 (INGN 201).

M. Vidaud, B. Escudier, A. Yver, 2003, Journal of virological methods.

The effects of rG-CSF on health-related quality of life in children with congenital agranulocytosis

G. Oster, P. Cleary, A. Yver, 1994, Quality of Life Research.

Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study.

I. Pollack, P. Kirschmeier, R. Packer, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial

David M. Thomas, J. Blay, J. Desai, 2019, The Lancet.

Pexidartinib for advanced tenosynovial giant cell tumor: results of the randomized phase 3 ENLIVEN study

J. Blay, C. Peterfy, W. Tap, 2019 .

The art of innovation: clinical development of trastuzumab deruxtecan and redefining how antibody-drug conjugates target HER2-positive cancers.

J. Soria, A. Yver, T. Agatsuma, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial.

H. Dombret, A. Krämer, N. Russell, 2019, The Lancet. Oncology.

Final results of a randomized controlled phase III trial (TAX 325) comparing docetaxel (T) combined with cisplatin (C) and 5-fluorouracil (F) to CF in patients (pts) with metastatic gastric adenocarcinoma (MGC)

J. Ajani, C. Boni, S. Tjulandin, 2005 .

Placebo-controlled phase III trial of lenograstim in bone-marrow transplantation

W. Siegert, C. Gisselbrecht, P. Biron, 1994, The Lancet.

Does detection of circulating ONYX-015 genome by polymerase chain reaction indicate vector replication?

A. Yver, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vandetanib for the Treatment of Thyroid Cancer

A. Yver, P. Langmuir, 2012, Clinical pharmacology and therapeutics.

Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.

Sung-Bae Kim, E. Tokunaga, H. Iwata, 2019, The New England journal of medicine.

Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study.

A. Kitano, A. Shimomura, T. Shimoi, 2017, The Lancet. Oncology.

Prostate-specific antigen (PSA) response as a surrogate endpoint for overall survival (OS): Analysis of the TAX 327 Study comparing docetaxel plus prednisone with mitoxantrone plus prednisone in advanced prostate cancer

I. Tannock, A. Yver, M. Eisenberger, 2005 .

Adjusting for patient selection suggests the addition of docetaxel to 5-fluorouracil–cisplatin induction therapy may offer survival benefit in squamous cell cancer of the head and neck

M. Mazumdar, J. Pignon, J. Bourhis, 2004, Anti-cancer drugs.

Placebo-controlled phase III study of lenograstim (glycosylated recombinant human granulocyte colony-stimulating factor) in aggressive non-Hodgkin's lymphoma: factors influencing chemotherapy administration. Groupe d'Etude des Lymphomes de l'Adulte.

B. Coiffier, H. Tilly, C. Gisselbrecht, 1997, Leukemia & lymphoma.

In vivo stimulation of neutrophil function by lenograstim (glycosylated rHug‐CSF) in oncohematologic patients: Results of a phase I trial

D. Blaise, P. Viens, A. Yver, 1994, Stem cells.

Phase I study of in vivo lenograstim (rHuG-CSF) for stem cell collection demonstrates improved neutrophil recovery after autologous bone marrow transplantation.

D. Blaise, P. Viens, A. Yver, 1994, Bone Marrow Transplantation.

Possible toxicity with the association of G-CSF and bleomycin

B. Coiffier, C. Gisselbrecht, F. Reyes, 1994, The Lancet.

Pharmacokinetic/pharmacodynamic analysis of adjuvant pegylated interferon α-2b in patients with resected high-risk melanoma

V. Sondak, A. Daud, A. Yver, 2010, Cancer Chemotherapy and Pharmacology.

Serum concentrations of pegylated interferon α-2b in patients with resected stage III melanoma receiving adjuvant pegylated interferon α-2b in a randomized phase III trial (EORTC 18991)

A. Eggermont, A. Testori, A. Yver, 2010, Cancer Chemotherapy and Pharmacology.

409PUpdated results of phase 1 study of DS-8201a in patients with HER2 expressing non-breast, non-gastric malignancies

H. Iwata, A. Shimomura, K. Tamura, 2017 .

Abstract P6-17-10: Dose justification for DS-8201a, a HER2-targeted antibody-drug conjugate, for HER2-positive breast cancer: Observed clinical data and exposure-response analyses

J. Baselga, H. Iwata, K. Tamura, 2019, Poster Session Abstracts.

Abstract PD3-07: Safety and efficacy results from a phase 1 study of DS-8201a in patients with HER2 expressing breast cancers

C. Redfern, H. Iwata, K. Yonemori, 2018 .

Abstract PD3-06: Updated results from DESTINY-breast01, a phase 2 trial of trastuzumab deruxtecan (T-DXd ) in HER2 positive metastatic breast cancer

Sung-Bae Kim, J. Baselga, E. Tokunaga, 2021 .

Efficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled Quantum-R Trial

H. Dombret, A. Krämer, N. Russell, 2018, Blood.

Assessment of trabectedin (T) induced liver toxicity with correlation to liver morphology in a phase I study of T + pegylated liposomal doxorubicin (PLD).

M. von Mehren, A. Yver, R. Cohen, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abstract GS1-03: [Fam-] trastuzumab deruxtecan (T-DXd; DS-8201a) in subjects with HER2-positive metastatic breast cancer previously treated with T-DM1: A phase 2, multicenter, open-label study (DESTINY-Breast01)

Sung-Bae Kim, E. Tokunaga, H. Iwata, 2020 .

Single agent activity of DS-8201a, a HER2-targeting antibody-drug conjugate, in heavily pretreated HER2 expressing solid tumors.

C. Redfern, H. Iwata, C. Shimizu, 2017 .

Recombinant human G-CSF (Lenograstim) for infectious complications in glycogen storage disease type Ib. Report of 7 cases.

Y. Bertrand, A. Yver, B. Bader-Meunier, 1994, Nouvelle revue francaise d'hematologie.

A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group.

R. Bouabdallah, H. Dombret, F. Mandelli, 1995, The New England journal of medicine.

A Comparison of Four Oncology External Control Arm Case Studies: Critiques From Regulatory and Health Technology Assessment Agencies.

M. Rosenlund, A. Yver, N. Gatto, 2022, Value in Health.

Osimertinib (AZD9291)-a science-driven, collaborative approach to rapid drug design and development.

A. Yver, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.